According to investigators at the University of Pittsburgh School of Medicine and Centocor R&D, a group of blood proteins can foresee which patients with idiopathic pulmonary fibrosis (IPF) - a progressive lung disease - are more likely to die within two years or live at least five years. The...
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH. "An orally bioavailable...
CareFusion (NYSE: CFN), a leading, global medical device company, announced the launch of SentrySuite, a new set of software applications that improve the quality of patient data and increase clinician productivity and efficiency in pulmonary and cardiopulmonary diagnostic settings. The...